Pomegra
Barcelona-based Health Force closed a €4.2M seed round led by LUMO Labs to expand AI agents that run insurance, claims and reporting work inside European hospitals.
Key Takeaways
- Health Force raised a €4.2M seed round in September 2026, led by LUMO Labs; valuation was not disclosed.
- Its agents handle 200,000+ patient cases a year in Italian hospitals, with 75% completed without human intervention.
- Funds go to new workflows, larger engineering and delivery teams, and entry into Germany, France and Spain.
Lead
Health Force, a Barcelona-headquartered startup building AI agents for hospital administration, raised a €4.2M seed round in September 2026. LUMO Labs led the round. Step Venture, Next Tier Ventures, Target Global and Calm/Storm Ventures also participated. The company did not disclose a valuation, and it did not state the size of its earlier pre-seed round.
The startup, co-founded in Vienna in 2022 by CEO Fadi Haddad and Juan Sebastián Suárez Valencia, now bases operations in Spain and runs an operations hub in Milan.
What Does Health Force Actually Sell?
Health Force sells software agents that log into a hospital's existing systems with their own credentials and perform back-office work under human supervision. The tasks include insurance workflows, prior authorizations, claims processing and regulatory reporting. Because the agents operate through the interfaces staff already use, hospitals do not need to build new integrations.
The company describes its platform as "deterministic-first," meaning it applies fixed logic wherever a rule can be written and reserves probabilistic models for the remainder. Every action is traceable, so staff can review what an agent did before relying on its output. That design targets the main objection to AI in clinical-adjacent settings: an administrator has to be able to explain why a claim was filed the way it was.
The pitch displaces two things: manual work by administrative staff, and the robotic process automation scripts that break when a screen layout changes. Haddad put it this way: "Hospitals don't need another dashboard; they need the work to get done."
How Much Is Deployed Today?
The agents currently handle more than 200,000 patient cases per year across leading Italian hospital groups, and 75% of those cases finish without human intervention. Customers include Humanitas and Gruppo San Donato in Italy and ULS Coimbra in Portugal.
Customer comments are specific about the mechanism. Humanitas COO Valeria Ingrosso said her teams now manage insurance operations alongside the agents. Ospedale Galeazzi CFO Giovanni Bonora said capacity grows with volumes. ULS Coimbra CIO Rui Gomes said no integration was required because the agent was trained to operate the hospital's systems as an employee would.
Those are reference customers chosen by the company, and revenue, contract values and renewal rates have not been published. The 75% automation figure is also an average across workflows of differing difficulty, so it says little about how the remaining quarter is distributed.
Why Is a Seed Round This Size Notable?
A €4.2M seed is a mid-sized check for a company that already has paying hospital groups in two countries and production volume in the hundreds of thousands of cases. That suggests the round funds scale-up rather than a first product. The prior pre-seed was small enough that it went undisclosed, which implies most of the commercial progress was achieved on limited capital.
The investor mix is also telling. LUMO Labs and Next Tier Ventures are early-stage specialists, while Target Global brings later-stage European and Middle East reach. Jorge Blasco of LUMO Labs said solutions that safely automate repetitive tasks are becoming increasingly necessary. Johannes Blaschke of Calm/Storm described a founding team that "truly understands healthcare."
What Are the Obstacles to Expansion?
Hospital deployment speed is the main constraint, and the company says so itself. Its own comment on the market is that each hospital has its own processes, integrations and accountability rules, which can slow rollout even when a workflow is technically automatable. Entering Germany, France and Spain adds different reimbursement systems, languages and data-protection expectations to that friction.
Competition is also unresolved. Revenue-cycle vendors, electronic health record providers and general-purpose agent platforms all target the same administrative work, and the EHR vendors control the systems that Health Force's agents log into. How those vendors respond to third-party agents using staff-style access will shape the startup's room to grow.
What Comes Next?
Health Force plans to widen its agent catalogue into quality reporting, clinical trial operations and resource optimization. It will also expand engineering and delivery teams, and open sales in Germany, France and Spain. Haddad has said that all hospitals in Europe will eventually manage their operations this way, a forecast the next two or three rollouts outside Italy and Portugal will begin to test.
Outlook
Health Force enters its next phase with live hospital deployments, a stated 75% no-touch rate and a lead investor focused on early-stage European technology. The open questions are commercial: unit economics, contract length and how quickly a new hospital goes live. Growth beyond Italy and Portugal will show whether its deterministic, traceable approach travels across health systems as easily as it has across Italian private hospital groups.
